327 related articles for article (PubMed ID: 9305589)
1. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation.
Munns AJ; De Voss JJ; Hooper WD; Dickinson RG; Gillam EM
Chem Res Toxicol; 1997 Sep; 10(9):1049-58. PubMed ID: 9305589
[TBL] [Abstract][Full Text] [Related]
2. Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation.
Cuttle L; Munns AJ; Hogg NA; Scott JR; Hooper WD; Dickinson RG; Gillam EM
Drug Metab Dispos; 2000 Aug; 28(8):945-50. PubMed ID: 10901705
[TBL] [Abstract][Full Text] [Related]
3. Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats.
Yamazaki H; Komatsu T; Takemoto K; Saeki M; Minami Y; Kawaguchi Y; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):427-34. PubMed ID: 11259327
[TBL] [Abstract][Full Text] [Related]
4. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.
Zhao SX; Dalvie DK; Kelly JM; Soglia JR; Frederick KS; Smith EB; Obach RS; Kalgutkar AS
Chem Res Toxicol; 2007 Nov; 20(11):1649-57. PubMed ID: 17907785
[TBL] [Abstract][Full Text] [Related]
5. Differences in cytochrome P450-mediated biotransformation of 1,2-dichlorobenzene by rat and man: implications for human risk assessment.
Hissink AM; Oudshoorn MJ; Van Ommen B; Haenen GR; Van Bladeren PJ
Chem Res Toxicol; 1996 Dec; 9(8):1249-56. PubMed ID: 8951226
[TBL] [Abstract][Full Text] [Related]
6. P450 2C18 catalyzes the metabolic bioactivation of phenytoin.
Kinobe RT; Parkinson OT; Mitchell DJ; Gillam EM
Chem Res Toxicol; 2005 Dec; 18(12):1868-75. PubMed ID: 16359177
[TBL] [Abstract][Full Text] [Related]
7. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4.
Komatsu T; Yamazaki H; Asahi S; Gillam EM; Guengerich FP; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Nov; 28(11):1361-8. PubMed ID: 11038165
[TBL] [Abstract][Full Text] [Related]
8. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac.
Shen S; Marchick MR; Davis MR; Doss GA; Pohl LR
Chem Res Toxicol; 1999 Feb; 12(2):214-22. PubMed ID: 10027801
[TBL] [Abstract][Full Text] [Related]
9. Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to covalent binding of its reactive intermediate.
Masubuchi Y; Igarashi S; Suzuki T; Horie T; Narimatsu S
J Pharmacol Exp Ther; 1996 Nov; 279(2):724-31. PubMed ID: 8930177
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of the cytochrome P450 mechanism-based inhibitor N-benzyl-1-aminobenzotriazole to products that covalently bind with protein in guinea pig liver and lung microsomes: comparative study with 1-aminobenzotriazole.
Woodcroft KJ; Webb CD; Yao M; Weedon AC; Bend JR
Chem Res Toxicol; 1997 May; 10(5):589-99. PubMed ID: 9168258
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the NADPH-dependent covalent binding of [14C]halothane to human liver microsomes: a role for cytochrome P4502E1 at low substrate concentrations.
Madan A; Parkinson A
Drug Metab Dispos; 1996 Dec; 24(12):1307-13. PubMed ID: 8971135
[TBL] [Abstract][Full Text] [Related]
12. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.
Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z
Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217
[TBL] [Abstract][Full Text] [Related]
13. Phenytoin metabolism to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in man, cat and rat in vitro and in vivo, and susceptibility to phenytoin-induced gingival overgrowth.
Kamali F; Ball DE; McLaughlin WS; Seymour RA
J Periodontal Res; 1999 Apr; 34(3):145-53. PubMed ID: 10384402
[TBL] [Abstract][Full Text] [Related]
14. Bioactivation of coumarin in rat olfactory mucosal microsomes: Detection of protein covalent binding and identification of reactive intermediates through analysis of glutathione adducts.
Zhuo X; Zhao W; Zheng J; Humphreys WG; Shu YZ; Zhu M
Chem Biol Interact; 2009 Oct; 181(2):227-35. PubMed ID: 19576871
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins.
Cai Y; Baer-Dubowska W; Ashwood-Smith MJ; Ceska O; Tachibana S; DiGiovanni J
Chem Res Toxicol; 1996 Jun; 9(4):729-36. PubMed ID: 8831817
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in rats in the metabolism of phenytoin to 5-(3,4-dihydroxyphenyl)-5-phenylhydantoin.
Billings RE
J Pharmacol Exp Ther; 1983 Jun; 225(3):630-6. PubMed ID: 6864524
[TBL] [Abstract][Full Text] [Related]
17. Oxygen-18 incorporation studies of the metabolism of phenytoin to the catechol.
Billings RE; Fischer LJ
Drug Metab Dispos; 1985; 13(3):312-7. PubMed ID: 2861989
[TBL] [Abstract][Full Text] [Related]
18. In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4.
Sahali-Sahly Y; Balani SK; Lin JH; Baillie TA
Chem Res Toxicol; 1996 Sep; 9(6):1007-12. PubMed ID: 8870989
[TBL] [Abstract][Full Text] [Related]
19. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved.
He K; Talaat RE; Pool WF; Reily MD; Reed JE; Bridges AJ; Woolf TF
Drug Metab Dispos; 2004 Jun; 32(6):639-46. PubMed ID: 15155556
[TBL] [Abstract][Full Text] [Related]
20. Protein covalent binding of maxipost through a cytochrome P450-mediated ortho-quinone methide intermediate in rats.
Zhang D; Ogan M; Gedamke R; Roongta V; Dai R; Zhu M; Rinehart JK; Klunk L; Mitroka J
Drug Metab Dispos; 2003 Jul; 31(7):837-45. PubMed ID: 12814959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
